SEARCH:   Advanced

Blood, 15 January 2007, Vol. 109, No. 2, pp. 786-791. Prepublished online as a Blood First Edition Paper on August 3, 2006; DOI 10.1182/blood-2006-05-024844. This Article Full Text (PDF) All Versions of this Article: blood-2006-05-024844v1 109/2/786    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Spoo, A. C Articles by Burger, J. A Search for Related Content PubMed PubMed Citation Articles by Spoo, A. C Articles by Burger, J. A Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted May 22, 2006 Accepted July 14, 2006 CXCR4 is a prognostic marker in Acute Myelogenous Leukemia Anke C Spoo, Michael Lubbert, William G Wierda, and Jan A Burger* Department of Medicine 1, Freiburg University Hospital, Freiburg, Germany Leukemia Department, The University of Texas, MD Anderson Cancer Center, Houston, Texas * Corresponding author; email: jaburger{at}mdanderson.org. CXCR4 chemokine receptors retain hematopoietic progenitors and leukemia cells within the marrow microenvironment. We prospectively evaluated the prognostic implication of CXCR4 in 90 consecutive patients with acute myelogenous leukemia by flow cytometry. Patients were divided into groups with low (n=32), intermediate (n=26), or high (n=32) CXCR4 expression, as defined by CXCR4 mean fluorescence intensity ratio thresholds of < 5, 5 to 10, or > 10, respectively. We found that low CXCR4 expression on AML cells correlated with a better prognosis, resulting in a longer relapse-free and overall survival of 24.3 ± 2.9 months for low CXCR4 expressing patients, compared to 17.4 ± 3.4 months for intermediate, and 12.8 ± 2 months (mean ± SEM) for patients with high expression. In univariate analyses, CXCR4 expression, cytogenetics, white cell count, and LDH predicted for shorter survival. Multivariate analysis revealed CXCR4 expression and unfavorable cytogenetics as independent prognostic factors. We conclude that CXCR4 expression in AML is an independent prognostic predictor for disease relapse and survival that can rapidly and easily be determined at disease presentation. These findings warrant further investigation into the role of CXCR4 in AML, and suggest that CXCR4 should be incorporated into the risk assessment of AML patients. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: R. Grundler, L. Brault, C. Gasser, A. N. Bullock, T. Dechow, S. Woetzel, V. Pogacic, A. Villa, S. Ehret, G. Berridge, et al. Dissection of PIM serine/threonine kinases in FLT3-ITD-induced leukemogenesis reveals PIM1 as regulator of CXCL12-CXCR4-mediated homing and migration J. Exp. Med., August 31, 2009; 206(9): 1957 - 1970. [Abstract] [Full Text] [PDF] S. W. Lane, D. T. Scadden, and D. G. Gilliland The leukemic stem cell niche: current concepts and therapeutic opportunities Blood, August 6, 2009; 114(6): 1150 - 1157. [Abstract] [Full Text] [PDF] C. N. Abboud Another nail in the AML coffin Blood, June 11, 2009; 113(24): 6045 - 6046. [Full Text] [PDF] B. Nervi, P. Ramirez, M. P. Rettig, G. L. Uy, M. S. Holt, J. K. Ritchey, J. L. Prior, D. Piwnica-Worms, G. Bridger, T. J. Ley, et al. Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100 Blood, June 11, 2009; 113(24): 6206 - 6214. [Abstract] [Full Text] [PDF] M. A. Schroeder, M. P. Rettig, P. Ramirez, and J. F. DiPersio Optimal Mobilization of Normal and Leukemic Stem Cells via Modulation of Chemokine and Integrin Axes Am. Assoc. Cancer Res. Educ. Book, April 18, 2009; 2009(1): 15 - 22. [Full Text] [PDF] M. Fiegl, I. Samudio, K. Clise-Dwyer, J. K. Burks, Z. Mnjoyan, and M. Andreeff CXCR4 expression and biologic activity in acute myeloid leukemia are dependent on oxygen partial pressure Blood, February 12, 2009; 113(7): 1504 - 1512. [Abstract] [Full Text] [PDF] P. S. Becker, K. J. Kopecky, A. N. Wilks, S. Chien, J. M. Harlan, C. L. Willman, S. H. Petersdorf, D. L. Stirewalt, T. Papayannopoulou, and F. R. Appelbaum Very late antigen-4 function of myeloblasts correlates with improved overall survival for patients with acute myeloid leukemia Blood, January 22, 2009; 113(4): 866 - 874. [Abstract] [Full Text] [PDF] R. M. Stone Genetically Defined Prognostic Factors and Novel Therapeutics for AML ASCO Educational Book, January 1, 2008; 2008(1): 280 - 284. [Abstract] [Full Text] [PDF] W. Zhang, J.-M. Navenot, N. M. Frilot, N. Fujii, and S. C. Peiper Association of Nucleophosmin Negatively Regulates CXCR4-Mediated G Protein Activation and Chemotaxis Mol. Pharmacol., November 1, 2007; 72(5): 1310 - 1321. [Abstract] [Full Text] [PDF] O. Bruserud, A. Ryningen, A. M. Olsnes, L. Stordrange, A. M. Oyan, K. H. Kalland, and B. T. Gjertsen Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells Haematologica, March 1, 2007; 92(3): 332 - 341. [Abstract] [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020